Successful Treatment of Synchronous Double Lung and Colon Cancers Using Immune Checkpoint Inhibitors
Abstract
We herein report a case of successfully treated synchronous advanced cancers: programmed death-ligand1 (PD-L1)-negative squamous cell carcinoma of the left upper lung lobe and adenocarcinoma of the ascending colon. As lung cancer was prioritized as the primary therapeutic target, the patient received a combination of anti-PD-L1 and anti-cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibodies, along with chemotherapy (the POSEIDON regimen). This approach proved effective against both lung and colon cancer. Subsequent testing revealed high-frequency microsatellite instability (MSI-H) in the colon cancer. These findings highlight the therapeutic potential of combined anti-PD-L1 and anti-CTLA-4 antibodies in the treatment of PD-L1-negative lung and MSI-H colorectal cancers.
Related
- Up-Front Immune Checkpoint Inhibitors in Patients with Multiple Synchronous Primary Tumors, Including dMMR/MSI-H Gastrointestinal Malignancies: A Case Series and Review of the Literature.
- Outcomes of Patients with Rare Cancers Treated with Immune Checkpoint Inhibitors with and Without Lung and/or Liver Metastases (NCI/SWOG S1609).
- Integration of Immune checkpoint inhibitors within the definitive radiotherapy-based treatment continuum for locally advanced mucosal head and neck squamous cell carcinoma: a scoping review protocol
- Immune Checkpoint Inhibitors: Sculpting the Landscape of Endometrial Cancer Treatment
- Mechanisms of resistance to immune checkpoint inhibitors in renal cell carcinoma and novel treatment strategies
BibTeX
@article{matsuoka2026successful,
title = {{Successful Treatment of Synchronous Double Lung and Colon Cancers Using Immune Checkpoint Inhibitors}},
author = {Shuichi Matsuoka and Hirokazu Tokuyasu and Katsunori Arai and Hiromitsu Sakai and Chika Esumi and Akira Yamasaki},
journal = {Internal Medicine},
year = {2026},
month = sep,
doi = {10.2169/internalmedicine.6293-25},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/65/17/65_6293-25/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Successful Treatment of Synchronous Double Lung and Colon Cancers Using Immune Checkpoint Inhibitors
AU - Shuichi Matsuoka
AU - Hirokazu Tokuyasu
AU - Katsunori Arai
AU - Hiromitsu Sakai
AU - Chika Esumi
AU - Akira Yamasaki
PY - 2026
DA - 2026/09/01
JO - Internal Medicine
DO - 10.2169/internalmedicine.6293-25
UR - https://www.jstage.jst.go.jp/article/internalmedicine/65/17/65_6293-25/_article
AB - We herein report a case of successfully treated synchronous advanced cancers: programmed death-ligand1 (PD-L1)-negative squamous cell carcinoma of the left upper lung lobe and adenocarcinoma of the ascending colon. As lung cancer was prioritized as the primary therapeutic target, the patient received a combination of anti-PD-L1 and anti-cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibodies, along with chemotherapy (the POSEIDON regimen). This approach proved effective against both lung and colon cancer. Subsequent testing revealed high-frequency microsatellite instability (MSI-H) in the colon cancer. These findings highlight the therapeutic potential of combined anti-PD-L1 and anti-CTLA-4 antibodies in the treatment of PD-L1-negative lung and MSI-H colorectal cancers.
SN - 1349-7235
SN - 0918-2918
ER -